Optimal Dose of Zanubrutinib to Treat Adult Immune Thrombocytopenia
Clinical trial NCT07315373 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07315373
- Sponsor
- Peking University People's Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-12-25
- Primary completion
- 2028-12-30
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.